Ceva Sante Animale

Nippon Zeon Company, Ltd.

Zeon Corporation

Shionogi Company Limited

Ceva Santa Animale

Sakiko Saeki

Shuji Saito

Mayumi Kubomura

Ayumi Fujisawa

Shuji Saitoh

Noboru Yanagida

Kouichi Kamogawa

Ryohei Ogawa

Takashi Okuda

Yoshiyuki Hayashi

Yoshikazu Iritani

Shigemi Aoyama

Ikuroh Ohsawa

Setsuko Ohkawa

Kazunari Sawaguchi

Kiyohito Takahashi

Hirono Funato

The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.

Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species

The present invention relates to a recombinantherpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.

A recombinant herpesvirus (excluding infectious laryngotracheitis virus) having a DNA that encodes a polypeptide comprising 429 amino acids at the amino terminal end of a protein encoded by the gB gene of infectious laryngotracheitis virus or a polypeptide in which one or a plurality of amino acids have been deleted, added, or substituted in said polypeptide.

Recombinant herpesvirus and uses thereof

Recombinant Avipox virus encoding polypeptide of mycoplasma

A recombinant Avipoxvirus having inserted exogenous DNA in a DNA region non-essential to proliferation of Avipoxvirus is provided. The recombinant Avipoxvirus is produced by inserting a promoter and exogenous DNA capable of expression under its control into a DNA region non-essential to proliferation of Avipoxvirus, utilizing DNA coding for a readily detectable enzyme, or, non-homologous DNA fragment.

Recombinant avipoxvirus

A recombinant Avipoxvirus having inserted all or a part of cDNA coding for Newcastle disease virus-derived hemagglutinin neuraminidase in a genome region non-essential to proliferation of Avipoxvirus is provided. The recombinant Avipoxvirus is utilizable as vaccine for fowl.

Growing community of inventors

Tokyo, Japan

Sakiko Saeki